A b s t r a c t
Improved care of patients with small B-cell lymphomas (SBCLs) is likely to result from the ongoing discovery of molecular markers that better define these malignant neoplasms. We identified multiple gene loci whose DNA methylation patterns differed between 3 types of SBCL: B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, and grades I and II follicular lymphoma. This analysis was performed using an oligonucleotide microarray that allowed determination of the DNA methylation status of 156 loci in 38 genes. Combined bisulfite restriction analysis and methylation-specific polymerase chain reaction were used to validate the differential methylation of 6 of these genes. By using non-Hodgkin lymphoma cell lines as models, these genes were examined further for methylation and gene expression relationships. This study illustrates nonrandom epigenetic alterations in SBCLs that seem to preferentially involve lymphomas of germinal center derivation.
Approximately 54,000 new cases of non-Hodgkin lymphoma (NHL) are diagnosed in the United States annually. Together, B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL), mantle cell lymphoma (MCL), and grades I and II follicular lymphoma (FLI/FLII) constitute one third of all NHL cases. 1 The NHLs B-CLL/SLL and FLI/FLII generally are thought to be of low aggressiveness, but they still exhibit a spectrum of clinical behavior. B-CLL/SLL is a lymphoma of at least 2 subtypes comprising pre-germinal center and post-germinal center derivation; MCL also is of pre-germinal center derivation, and FLI/FLII derives from germinal centers of lymphoid tissues. Many patients with B-CLL/SLL and FLI/FLII have a relatively good prognosis, with median survival of approximately 7 to 10 years, but the diseases usually are not curable in advanced clinical stages. MCL typically is more rapidly progressive than these other small Bcell lymphomas (SBCLs). Diagnostically, it usually is possible to discern each type of SBCL from the other on the basis of histologic pattern, but there is considerable overlap in biology, clinical disease, and gene expression between subtypes. DNA microarrays have made it possible to simultaneously measure the expression of thousands of individual genes and have been used to identify altered gene expression of SBCLs, including MCL, B-CLL/SLL, and FL. 2 This approach has been used to identify genes with patterns of expression that identify previously unrecognized but clinically distinct subtypes of MCL and B-CLL/SLL. Although a number of gene expression abnormalities have been defined, it has become accepted that epigenetic alterations, including histone deacetylation and DNA methylation, also contribute to the cell biology of many cancers 3 and might, in fact, be responsible for some of the gene expression abnormalities.
In normal cells, DNA methylation usually occurs by adding a methyl group to the fifth carbon position of cytosine within a 5'-CG-3' palindrome (CpG with p denoting the phosphate group) during DNA replication. 4 Across the genome, approximately 80% of CpG dinucleotides are heavily methylated, but some remain unmethylated in specific GC-rich regions (G+C content, >50%-60%), called CpG islands. These 0.2-to 1-kilobase-long DNA sequences frequently are located in the promoters and first exon regions of 40% to 50% of all genes. The rest may be located in the intronic or other exonic regions of the genes or in regions containing no genes.
In cancer cells, patterns of DNA methylation are altered. [3] [4] [5] Studies have indicated that promoter (including the first exon) CpG island hypermethylation is a frequent epigenetic event in many types of cancer. This epigenetic process can result in gene silencing via alteration of local chromatin structure in the 5' end of regulatory regions, preventing normal interaction of the promoters with the transcriptional machinery. If this occurs in genes critical to growth inhibition, the silencing event could promote tumor progression. Few published reports have focused on the identification of genes with methylation profiles that differ between currently recognized SBCL subtypes. By using a previously described microarray-based method of site-specific methylation analysis, [6] [7] [8] [9] we examined patterns of CpG island methylation in SBCLs, including MCL, B-CLL/SLL and FLI/FLII that approximate the pre-germinal center and germinal center stages of differentiation. We validated the methylation patterns of 6 of these genes using methylation-specific polymerase chain reaction (PCR) and combined bisulfite restriction analysis (COBRA) and analyzed the relationship of methylation and gene expression of 4 genes in lymphoma cell lines. Methylated genes identified in the course of these studies are of biologic interest and represent candidate diagnostic or prognostic markers. This will facilitate a better overall understanding of the multiplicity of genetic and epigenetic effects in SBCLs.
Materials and Methods

Tissue Samples
Tissue samples were obtained from patients undergoing diagnostic evaluation for suspected lymphoma at the Ellis Fischel Cancer Center, Columbia, MO, in compliance with the local institutional review board. Specimens used in the study were identified through a computer-based search for cases of FLI/FLII (excluding cases noted to be grade III), MCL (excluding cases noted to have blastoid morphologic features), and B-CLL/SLL (irrespective of the level of CD38 expression). Cyclin D1 overexpression was validated by immunohistochemical analysis for a subset of MCL cases (data not shown).
Retrospective analysis of flow cytometric data obtained at the time of diagnosis for a subset of cases revealed that FLI/FLII specimens comprised approximately 64% neoplastic B cells (FLI, n = 14; FLII, n = 12; range, 50%-75%), MCL specimens comprised approximately 72% neoplastic cells (n = 14; range, 32%-94%), and B-CLL/SLL specimens comprised approximately 85% neoplastic cells (n = 15; range, 60%-95%) (data not shown). Thus, for comparative purposes, tumor cells were predominant. All cases of B-CLL/SLL had peripheral blood and bone marrow involvement and, thus, technically were categorized as chronic lymphocytic leukemia, a subset of B-CLL/SLL in the World Health Organization classification. 1 All of these are referred to as B-CLL/SLL in this article.
Bisulfite Treatment and PCR Amplification for Microarray Hybridizations
Bisulfite treatment of genomic DNA was done with minor modifications as described. 6 For the PCR amplification of the bisulfite-treated sense strand of the genes used for class prediction and discovery, the primers were designed according to the guidelines of Clark et al, 10 ensuring preferred amplification of DNA fragments with complete bisulfite conversion. Note that primers were designed to hybridize to DNA fragments containing no CpG dinucleotides, thus allowing unbiased amplification of methylated and unmethylated alleles.
For the methylation profiling of lymphoma samples, CpG sites from regulatory regions of the genes listed in ❚Table 1❚ were analyzed. Seven or eight fragments were amplified in parallel using multiplex PCR. The following protocol was used for multiplex PCR reactions: 10 ng of bisulfite-treated DNA as the template, 2 pmol of each primer (7 or 8 primer pairs), 1.6 mmol/L of deoxynucleoside triphosphates, and 1 U of Taq polymerase (HotStarTaq, Qiagen, Hilden, Germany) in reaction buffer supplied with the enzyme with 3.5 mmol/L of magnesium chloride were incubated in 25 µL total volume. After activation of the enzyme (15 minutes, 96°C), the incubation times and temperatures were 95°C for 1 minute followed by 39 cycles (95°C for 1 minute, 55°C for 45 seconds, and 65°C for 75 seconds) and 65°C for 10 minutes.
Microarray Hybridizations
❚Figure 1❚ outlines the oligonucleotide microarray strategy for DNA methylation analysis. The PCR-amplified products contain pools of DNA fragments with bisulfite-converted nucleotides owing to their differential methylation status. As shown, the unmethylated allele of a given DNA sequence is expected to have unmethylated cytosines converted to thymine, whereas this CpG sequence remains unchanged in the methylated allele. All PCR products obtained from an individual sample were mixed and hybridized to glass slides carrying a pair of immobilized oligonucleotides for each CpG position.
Oligonucleotides with a C6-amino modification at the 5' end were spotted with 4-fold redundancy on activated glass slides. For each analyzed CpG position, 2 oligonucleotides, N (2-16) -CG-N (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) and N (2-16) -TG-N (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) , reflecting the methylated and unmethylated status of the CpG dinucleotides, were spotted and immobilized on the glass array. Hybridization conditions were selected to allow the detection of the single nucleotide differences between the TG and CG variants. The microarrays contained 156 CpG sites from 38 genes that were selected because they are related mostly to the cell cycle (Table  1 ) and were hybridized with Cy5-labeled PCR fragments as described. 7 Subsequently, the fluorescent images of the hybridized slides were obtained using a GenePix 4000 microarray scanner (Axon Instruments, Union City, CA). Hybridization experiments were repeated at least 6 times for each sample. For each hybridization experiment, the median spot intensities of both CG and TG detection oligonucleotides were determined for each CpG position. The methylation proportion was calculated as follows: CG/(CG+TG). The mean methylation proportion for all 6 repetitions was used for further analyses.
Combined Bisulfite Restriction Analysis
Aliquots of 2 µg of genomic DNA were treated with sodium bisulfite. For the preparation of 100% methylated DNA, a blood DNA sample was treated with cytosine methyltransferase SssI that methylates all cytosine residues of CpG dinucleotides in the genome. Sodium bisulfite modification of the test and SssI-treated DNA samples were then performed as described in the preceding text. Bisulfite-treated genomic DNA (100-200 ng) was used as a template for PCR with specific primers located in the CpG island regions of multiple genes. For COBRA, after amplification, PCR products were digested with the restriction enzyme BstUI (New England Biolabs, Beverly, MA), which recognizes sequences unique to the methylated and bisulfite-unconverted alleles. The digested and undigested control DNA samples were separated in parallel on 3% agarose gels, stained with SYBR Green (Applied Biosystems, Foster City, CA), and quantified using the Kodak gel documentation system (Kodak, Rochester, NY). Primers and restriction enzymes are listed in ❚Table 2❚.
Methylation-Specific PCR
For methylation-specific PCR (MSP), 2 µg of genomic DNA were treated with sodium bisulfite according to the manufacturer's recommendations (CpGenome; Intergen, Purchase, NY), and 100 ng of bisulfite-treated DNA was used for each assay. Allele-specific primers were designed to differentiate methylated and unmethylated sequences. The primers used and their sequences are listed in Table 2 .
Confirmation of Gene Expression by Real-Time Reverse Transcriptase-PCR
Total RNA (2 µg) was pretreated with DNase I to remove potential DNA contaminants and reverse-transcribed in the presence of SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). The complementary DNA (cDNA) generated was used for PCR amplification with appropriate reagents in QPCR mix (ABgene, Rochester, NY) as recommended by the manufacturer. The Taqman probe and primer sets for all genes were purchased from Applied Biosystems. The reaction was carried out in 40 to 45 cycles using a Smart Cycler Real-Time PCR machine (Cepheid, Sunnyvale, CA). All cDNA samples were synthesized in parallel and PCR reactions run in triplicate. Separate parallel reactions were run for GAPDH (glyceraldehyde-3-phosphate dehydrogenase) cDNA using a series of diluted cDNA samples as templates to generate standardization curves. The messenger RNA levels were derived from the standardization curves and expressed as relative changes after normalization to those of GAPDH.
Statistical Methods
The most important step in data analysis is the identification of the most informative CpG positions that are relevant in discriminating the classes of SBCLs. In this study, the Wilcoxon rank statistic was used to calculate corresponding P values across all NHL cases for each CpG position. To correct for multiple testing, a Bonferroni-type correction method was used to adjust the P values. 9 The mean value across all cases for a given locus was calculated, as was the deviation from the mean for each case. The ranked matrix representation illustrates the deviation of each case from the mean for the samples under study. The shown CpG positions are ranked according to the statistical significance of their class discrimination. The most significant CpGs are displayed at the bottom of the matrix representation.
Results and Discussion
NHLs Are Morphologically and Biologically Heterogeneous
It is recognized widely that NHL is not one but many diseases and that indolent NHLs also constitute a remarkably heterogeneous group. For this study, NHL cases were classified by morphologic and histologic features based on the World Health Organization classification and by flow cytometric confirmation of the immunophenotype. MCL cases all were positive for CD19 and CD5 and negative for CD23 and brightly expressed monoclonal surface immunoglobulin (sIg). More than 95% of MCLs are known to carry the t(11;14) chromosomal translocation that results in juxtaposition of the immunoglobulin heavy-chain (IgH) (14q32) locus with cyclin D1 (CCND1) gene sequences (11q13). B-CLL/SLL cases were all positive for CD19, CD5, CD23 and dimly expressed monoclonal sIg, but only 4 of 14 were positive for CD38, which typically is associated with cases that have undergone somatic hypermutation of immunoglobulin genes. 11 Based on ----TG----3'  3'----AC----5'   5'----CA----3'  3'----GT--- ----CG----3'  3'----GC----5'   5'----CG----3'  3'----GC--- a paired t test, there was no significant difference (P > .05) in methylation between CD38+ and CD38-cases for any of the tested gene loci; thus, for further evaluation, these all were classified together as B-CLL/SLL. Cases of FLI and FLII known to carry the t(14;18) chromosomal translocation that results in juxtaposition of the immunoglobulin IgH locus with bcl-2 gene sequences also were positive for CD19 and additionally expressed CD10 and bright monoclonal sIg but were negative for CD5 and CD23. Improved understanding of the biology of SBCLs is likely to result from the ongoing discovery of molecular markers that better define these malignant neoplasms. We examined 156 loci involving 38 genes to identify those with DNA methylation patterns that differed between 3 types of SBCL: MCL, B-CLL/SLL, and FL. Whereas previously published studies generally have analyzed the gene expression profiles of SBCL, this study was intended to identify genes that are methylated differentially between 3 SBCL subtypes, a process that in some cases is linked to gene silencing. Rush et al 12 reported the methylation of a large number of genes in a small number of patients with B-CLL/SLL, but there is minimal overlap with the gene loci reported in this article.
Cellular differentiation in secondary lymphoid tissues typically is divided into 3 phases: pre-germinal center, germinal center, and post-germinal center stages ❚Figure 2❚. During the pre-germinal center phase, selection and recombination of 
Differential Methylation Occurs Nonrandomly
For this study, 156 loci involving 38 genes, mainly related to cell-cycle regulation, were examined (Table 1) . For each locus of each gene (y-axis) ❚Figure 3❚, the methylation proportion across all cases (x-axis) of MCL, B-CLL/SLL, FLI, and FLII was averaged (from 6 replicates of each) and then the variance from the mean was calculated for each individual case. In Figure 3 , red indicates methylation values more than the mean and green indicates values less than the mean. The color intensity corresponds to the magnitude of change. BCL2  CDKN2A  TP73  PTEN  TP73  RB1  AR  EGR4  MOS  CDKN1B  MGMT  MDR1  GP1bβ  CDC25A  MYC  BAK1  CDKN1C  RB1  MOS  MOS  TP73  GP1bβ  TP73  GP1bβ  CDKN1A  BCL2  MLH1  MOS  CDK4  GP1bβ  MLH1  BAK1  CDKN2B  AR Table 1 for the complete gene names.
MDR1
To determine differentially methylated sites between SBCLs, we first performed a ranked matrix analysis of the variances from the mean (Figure 3 ). There was no statistically significant difference (P > .05) in the methylation pattern of any studied gene locus between cases of FLI and FLII or of MCL and B-CLL/SLL (data not shown). Therefore, cases of FLI and FLII were grouped together for all further analyses, analogous to the situation with CD38+/CD38-B-CLL/SLL.
When comparing FLI/FLII with B-CLL/SLL (or MCL, data not shown), several markers with significant P values (P < .05) were observed between the 2 classes; in all of them, the FLI/FLII group appeared hypermethylated compared with B-CLL/SLL. Of the 156 loci involving 38 genes initially analyzed, genes ranked in decreasing order of significance are shown in ❚Figure 4❚, with the least significant at the top and the most significant at the bottom. Most of these were methylated preferentially in FLI/FLII, with the exception of the gene CDKN1C, in which a single locus was statistically methylated in MCL (P = .0002) but not in B-CLL/SLL compared with the FLI/FLII group. This methylation profiling not only provided a broader insight into differential gene methylation between these classes of NHL but also set the stage for further experimental validation of the differential methylation of specific genes and their association with gene silencing.
Confirmation of Microarray Observations by COBRA and MSP
Because the oligonucleotide microarray contains very site-specific probes and not all loci of every gene show the same methylation pattern with regard to classes of NHLs, it is important to use the microarray as a discovery tool and to confirm findings with further validation. In the case of B-CLL/SLL compared with FLI/FLII, the microarray revealed a total of 17 loci representing 12 genes that were methylated differentially (P < .05) and for MCL compared with FLI/FLII, a total of 20 loci representing 15 genes that were methylated differentially (P < .05). There were no loci that were methylated differentially between B-CLL/SLL and MCL or FLI compared with FLII (P > .05).
Thus, many genes were methylated differentially only at a single locus and, therefore, required additional confirmation. Indeed, the signal at 1 locus of CDKN1C seems to be CDK4  TP73  MDR1  RB1  HIC-1  CDK4  MYC  TP73  CDKN2B  BCL2  MLH1  CDKN1A  CDKN1C  GP1bβ  AR  BAK1  GP1bβ  CDKN2B  MLH1 Gene   CDK4  MOS  GP1bβ  CDKN1A  GP1bβ  TP73  MLH1  MYOD1  GP1bβ  CDKN2B  MOS  BCL-2  TP73  RB1  MLH1  CDK4  GP1bβ  BAK1  CDKN2B 
❚Figure 4❚ The ranked matrix algorithm was used to sort the CpG positions of individual genes between cases in comparisons of mantle cell lymphoma (MCL) vs follicular lymphoma, grades I and II (FLI/FLII) (A) and of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) vs FLI/FLII (B). Gene names are labeled along the left y-axis, and their P values (corrected for multiple testing) between groups based on methylation differences are shown on the right y-axis. All gene names in red type along the y-axis show P values < .05. The sample numbers and disease classes are shown along the x-axis. The methylation proportion relative to the mean of the group is expressed for each individual case as red (increased methylation compared with the mean), green (decreased methylation compared with the mean), or black (no difference). See Table 1 for the complete gene names.
methylated preferentially in MCL (P = .0002) in Figure 4 . However, not shown in this abbreviated figure (there were 156 loci in the complete microarray), is that 3 additional loci of the same gene showed no such methylation, and confirmation studies by COBRA revealed that 47% (7/15) of FLI/FLII and 7% (1/15) of B-CLLs/SLLs were methylated. The methylation status at the locus identified on the microarray could not be verified in MCL (data not shown). Because the oligonucleotide array probes very specific sites (2-3 CG dinucleotides) and the COBRA primers cover a much larger area, it was not unexpected that this situation might arise and, in fact, is the reason for validation studies. Nevertheless, the methylation microarray serves as a valuable discovery tool. To further confirm methylation status of a few other gene loci, 6 genes were selected for further confirmation by COBRA and MSP ❚Figure 5❚ using 15 cases each of B-CLL/SLL and FLI/FLII. Generally, the pattern of increased gene promoter methylation in FLI/FLII compared with B-CLL/SLL observed on the microarray was confirmed. The percentage of each gene methylated in each class of NHL is shown in Figure 5 . Some genes, such as MLH1, ESR1, and CDKN2A are known to show little promoter methylation in NHLs. This was reaffirmed in the present study; only 1 of 30 patient samples was methylated with each of these 3 genes. In the case of MLH1, this finding is consistent with the observation that few cases of low-grade NHL demonstrate microsatellite instability. 13 On the microarray, 2 of 4 MLH1 loci showed a significant difference (P = .026 and P = .0001), whereas the other 2 loci were not significant (P > .05). The ESR1 gene was not significant at any microarray locus comparing B-CLL/SLL with FLI/FLII or comparing MCL with FLI/FLII. COBRA analysis revealed a single case of FLI methylated and none in B-CLL/SLL. A single locus of CDKN2A was significant (P = .003) in comparing MCL with FLI/FLII but was confirmed as methylated in only 1 of 15 B-CLL/SLL samples and none of the 15 FLI/FLII samples.
Of the remaining 3 genes validated, FLI/FLII revealed methylation rates ranging from 33% to 47% of cases, whereas in B-CLL/SLL, the range was 0% to 7%. CDKN2B on the microarray showed significance in 2 of 4 loci (P = .0000007 and P = .0033) and was confirmed by MSP to be methylated in 33% of FLI/FLII samples and none of the B-CLL/SLL samples. GP1bβ is an interesting gene known to be involved in platelet function but not studied before in NHLs. Of 4 loci, 3 showed significant differences in methylation on the microarray, and COBRA revealed methylation in 33% of FLI/FLII samples but none of the B-CLL/SLL samples. Although microarray analysis demonstrated methylation of a single locus of the CDKN1C gene preferentially in MCL, confirmatory COBRA analysis across a larger region of the promoter revealed methylation in 47% of FLI/FLII samples but in only 7% of B-CLL/SLL cases.
Relationship of Methylation to Gene Expression
We also studied NHL cell lines to determine whether gene expression might be altered in conjunction with CpG island methylation and whether gene expression could be renewed after treatment with a demethylating agent (5-aza), a histone deacetylase inhibitor (TSA), or both ❚Figure 6❚. Quantitative real-time reverse transcriptase-PCR was performed using NHL cell lines that were untreated or were treated with 5-aza, TSA, or a combination of 5-aza and TSA. Peripheral blood lymphocytes were included as a normal control sample. Table 1 for the complete gene names.
The conditions for maximal reinduction of the genes differed somewhat between genes and among various NHL cell lines. For ESR1, simultaneous treatment with 5-aza and TSA was necessary for maximal gene expression in the Daudi and Raji cell lines, even though treatment with 5-aza produced some expression alone, and treatment with TSA did not or was minimal. For MLH1, there was no methylation by COBRA, and there was clear expression of messenger RNA, consistent with a nonmethylated gene promoter. With respect to our microarray finding of a weak preferential methylation of 2 loci of MLH1 in FLI/FLII and the lack of gene silencing, it has been reported that microsatellite instability is low in most indolent NHLs 13 and that a fairly high density of MLH1 methylation is required for gene silencing in colorectal cancer. 14 Thus, these cell line experiments confirm the findings of other studies whereby the relationships of DNA methylation, histone deacetylation, and gene expression are variable between genes. Whether these cell line experiments are directly applicable to primary human NHL cells is yet to be proven.
Independent Support for the Methylation Microarray Approach
To our knowledge, there have been no previously published studies comparing DNA methylation patterns among FL, MCL, and B-CLL/SLL. Cross-validation of reported results between laboratories is a good way to maximize microarray data interpretation. Although not many methylation microarray experiments have been reported on NHLs, validation of methylation and expression from published literature is still valuable.
Beyond our confirmation of some of the microarray data, certain of the other gene loci have been studied independently by our group and others and findings further support the microarray findings. Yang et al 15 reported that the AR gene was methylated selectively in a high proportion of male and female patients with FLI/FLII but not B-CLL/SLL or MCL and, in fact, was the strongest discriminator between these NHL classes on the microarray. Methylation of p73, differentially methylated in the microarray, was reported as not found in MCL or B-CLL/SLL but was present in approximately 10% of FL cases. 16 Our microarray study also showed a similar pattern, with preferential methylation involving FLI/FLII over B-CLL/SLL and MCL.
De novo methylation of CDKN2A (p16) and CDKN2B (p15) is reportedly a rare event in B-CLL/SLL, 17 and this finding was supported in our study whereby CDKN2B was methylated pref- 
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❚Figure 6❚ DNA methylation and gene expression analysis of selected genes in lymphoma cell lines. Samples were examined by combined bisulfite restriction analysis for methylation (A) and by reverse transcriptase-polymerase chain reaction for expression of messenger RNA for the specified genes (B). See Table 1 for the complete gene names. A, treated with 5-aza (a demethylating agent); AT, treated with 5-aza and TSA; C, untreated; T, treated with TSA (a histone deacetylase inhibitor).
lymphoma" cases (includes B-CLL/SLL) and approximately two thirds of FL cases; they also found no methylation of CDKN2A in lymphocytic lymphoma cases but found methylation in approximately one third of FL cases.
Summary
Oligonucleotide microarray technology has provided a useful discovery environment in which to gain broader insights into biologic DNA methylation in SBCLs. We demonstrate a coordinated view of DNA methylation at multiple gene loci that potentially relates to gene silencing, as in the case of AR. This microarray thus has proven a valuable discovery tool and allowed a broader picture of simultaneous methylation of multiple gene loci that can be expanded in future studies that might then lead to improved tools for diagnosis and/or prognosis.
It is important that this study also discovered a very interesting biologic finding that will stimulate further research: the preferential methylation of multiple gene promoters in germinal center tumors such as FLI/FLII compared with pre-germinal center tumors (MCLs and some B-CLL/SLLs) and post-germinal center tumors (subsets of B-CLL/SLL). The reasons for this are not entirely clear but might be related to the ongoing process of DNA strand breaks and repair (both effective and ineffective) that accompanies germinal center biology and, possibly, is carried over into germinal center NHLs.
